PEG-PLGA- anti-EpCAM RNA aptamer used for targeted delivery of doxorubicin to breast cancer cells

PolySciTech (www.polyscitech.com) provides a wide array of biodegradable block copolymers. Recently aptamer linked PLGA-PEG nanoparticles were investigated as a potential medicinal delivery treatment method for breast cancer by the Mashhad University of Medical Sciences in Iran. Read more: Alibolandi, Mona, Mohammad Ramezani, Fatemeh Sadeghi, Khalil Abnous, and Farzin Hadizadeh. "Epithelial cell adhesion molecule aptamer conjugated PEG–PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro." International journal of pharmaceutics 479, no. 1 (2015): 241-251. http://www.sciencedirect.com/science/article/pii/S0378517314009326

“Abstract: Targeted delivery of anti-cancer agents exclusively to tumor cells introduces an attractive strategy because it increases the therapeutic index compared with untargeted drugs. Aptamer conjugated nanoparticles that can specifically bind to the proteins on a tumor cell surface are capable nanoscale delivery systems for enhancing cellular uptake of chemotherapeutic agents. The epithelial cell adhesion molecule (EpCAM) as a cancer stem cell marker emerges as a versatile target for aptamer-based cancer therapy due to its high expression level in various adenocarcinoma cell lines and its very low expression level in normal cells. We developed EpCAM-targeted PEG–PLGA nanopolymersomes by covalently coupling the EpCAM aptamer to the surface of nanopolymersomes loaded with the anticancer agent doxorubicin via pH gradient method. The results indicated that doxorubicin was entrapped in PEG–PLGA nanopolymersomes with encapsulation efficiency and loading content of 91.25 ± 4.27% and 7.3 ± 0.34%, respectively. Over a period of 5 days, up to 8% of the DOX was released through this system. The doxorubicin-loaded aptamer conjugated nanopolymersomes exhibited efficient cell uptake and internalization, and were significantly more cytotoxic (P < 0.01) toward EpCAM-positive tumor cells (MCF-7) than non-targeted nanopolymersomes. Our data suggest that EpCAM-targeted nanopolymersomes will lead to an improved therapeutic index of doxorubicin to EpCAM positive cancer cells. Keywords: PEG–PLGA; Nanopolymersomes; EpCAM; Aptamer; Targeted drug delivery”